The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
Open accessAbstract
Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Methods: Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation. Results: Users ( N = 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible ( N = 812) reduced their GMI by 0.4% ± 0.4% ( P = 0.005) and increased their TIR by 12.1% ± 10.5% ( P < 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%, P < 0.0001) and TIR >70% (34.6% vs. 74.9%, P < 0.0001) when compared with pre-AHCL initiation. Conclusion: Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both generation 1 low-glucose-suspend33 and generation 2 hybrid closed-loop systems improve glycated haemoglobin concentrations, the time in target range and the time below target range in children, adolescents34 and adults.35-37”
From Blood glucose monitoring devices: current considerations (2023) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“AHCL systems continuously adjust basal insulin delivery every five minutes based on real‐time continuous glucose monitoring (CGM) data and automatically administer correction boluses in response to hyperglycemia, thereby facilitating the maintenance of glucose levels near predefined targets 8 .”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“The new parameters are born from the growing use of CGM measurements of time spent in different ranges with consensus on definitions of ranges and current goals.(1) For people with T1DM, except during pregnancy, the goals are to spend >70% of the time between the range of 70–180 mg/dL, <4% below 70 mg/dL, <1% below 54…”
BackgroundSelf-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies
Ioannidis, J. P. A. (2001) · JAMA · doi:10.1001/jama.286.7.821 · Cited by 919
Holman, N., Knighton, P., Kar, P., O'Keefe, J., Curley, M., Weaver, A., Barron, E., Bakhai, C., Khunti, K., Wareham, N. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30271-0 · Cited by 908
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & SKOLNIK, N. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 757
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 1×
“Users with ‡10 days of sensor glucose (SG) data after AHCL was enabled for the first time (post-AHCL) were included in the analysis, based on previous publications using a similar duration of time to estimate or determine CGM-derived metrics.(13,14) All data available were included, whether the system was in AHCL cont…”
MethodGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Self-citationAddala, A., Auzanneau, M., Miller, K., Maier, W., Foster, N., Kapellen, T., Walker, A., Rosenbauer, J., Maahs, D. M., & Holl, R. W. (2021) · Diabetes Care · doi:10.2337/dc20-0257 · Cited by 283
Collyns, O. J., Meier, R. A., Betts, Z. L., Chan, D. S. H., Frampton, C., Frewen, C. M., Hewapathirana, N. M., Jones, S. D., Roy, A., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2250 · Cited by 276
Self-citationOptimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control
Riddlesworth, T. D., Beck, R. W., Gal, R. L., Connor, C. G., Bergenstal, R. M., Lee, S., & Willi, S. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0455 · Cited by 266
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Monti, S., Grosso, V., Todoerti, M., & Caporali, R. (2018) · Rheumatology · doi:10.1093/rheumatology/key109 · Cited by 170
Hybrid closed‐loop therapy: Where are we in 2021?
Leelarathna, L., Choudhary, P., Wilmot, E. G., Lumb, A. N., Street, T., Kar, P. S., & Ng, S. M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14273 · Cited by 146
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 142
Isganaitis, E., Raghinaru, D., Ambler-Osborn, L., Pinsker, J. E., Buckingham, B. A., Wadwa, R. P., Ekhlaspour, L., Kudva, Y. C., Levy, C. J., Forlenza, G. P., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0572 · Cited by 115
Beato-Víbora, P. I., Gallego-Gamero, F., Ambrojo-López, A., Gil-Poch, E., Martín-Romo, I., & Arroyo-Díez, F. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0037 · Cited by 88
Runge, A. S., Kennedy, L., Brown, A. S., Dove, A. E., Levine, B. J., Koontz, S. P., Iyengar, V. S., Odeh, S. A., Close, K. L., Hirsch, I. B., et al. (2018) · Clinical Diabetes · doi:10.2337/cd17-0094 · Cited by 87
Renard, É., Ikegami, H., Vianna, A. G. D., Pozzilli, P., Brette, S., Bosnyák, Z., Lauand, F., Peters, A. L., Pilorget, V., Jurišić‐Eržen, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3430 · Cited by 83
Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S., & Nørgaard, K. (2020) · Diabetes Care · doi:10.2337/dc20-0909 · Cited by 72
Petrovski, G., Khalaf, F. A., Campbell, J., Umer, F., Almajaly, D., Hamdan, M., & Hussain, K. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01607-4 · Cited by 61
Kelty, E. A., Tran, D. T., Atkinson, A., Preen, D. B., & Havard, A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0241 · Cited by 8
Shin, J., Chen, X., Liu, M., Huang, S., Cordero, T. L., Rhinehart, A. S., & Vigersky, R. A. (2021) · Diabetes · doi:10.2337/db21-706-p · Cited by 1
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Da Silva J, , Arrieta A, , Castaneda J, et al.: Real-world Performance of the MiniMed™ 780G System: impact of initiating automated basal and correction boluses. Diabetes Technol Ther, 2021; 23:A79–A80.
- Habif S, , Singh H, , Manning M, et al.: Quality of life outcomes and glycemic control from the T:slim X2 Pump with Control-IQ Technology—Real World Observations from the CLIO Study. Diabetes Technol Ther, 2021; 23:A-66.
- Da Silva J, , Velado K, , Agrawal P, et al.: Real-life use and performance of the MiniMed™ 670G System in Europe. Diabetes Technol Ther, 2020; 22:A96–A97.
Cited by
Sorted by citations
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Yogev, D., Goldberg, T., Arami, A., Tejman‐Yarden, S., Winkler, T. E., & Maoz, B. M. (2023) · APL Bioengineering · doi:10.1063/5.0152290 · Cited by 147
A Systematic Review of Commercial Hybrid Closed-Loop Automated Insulin Delivery Systems
Peacock, S., Frizelle, I., & Hussain, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01394-5 · Cited by 122
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system
Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Silva, J. D., Shin, J., & Cohen, O. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14807 · Cited by 108
Self-citation
Metadata
- Authors
- Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O.
- Affiliations
- Medtronic (Switzerland) (CH)
- Ospedale Papa Giovanni XXIII (IT)
- University of Ljubljana (SI)
- Medtronic (Netherlands) (NL)
- Medtronic, Northridge, California, USA.
- Medtronic (United States) (US)
- Corresponding author
- Cohen, Ohad
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2022-01-31
- Volume
- 24
- Issue
- 2
- Pages
- 113-119
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- PMC
- PMC8817690
- OpenAlex
- W3201039184
- Cited by
- 229
- References
- 26
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 61 · 2023: 67 · 2022: 36
- FWCI
- 30.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Technology & Therapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- MiniMed 780G, hybrid closed-loop insulin delivery, type 1 diabetes, real-world performance, glucose management indicator, time in range, glycemic control, continuous glucose monitoring
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Retrospective Studies, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
